Catalyst Wire Dossier Catalyst Wire Dossier

EMRELIS

Telisotuzumab vedotin · AbbVie Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EMRELIS, covering 2025-05-14 to 2025-05-14. Get the full timeline:

Most recent: FDA Approved: EMRELIS — Original Application (AbbVie Inc.)

See pricing